Philip Gold, MD
Medical Oncology · Seattle, WANPI 1265516983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 67.7% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $160, more than ten times the $15 reported in 2020. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.
Across 4 payments — averaging $48.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$132
- Osteocentric Technologies, Inc.$29
- Genentech USA, Inc.$19
- Coherus Oncology, Inc.$15
Across 229 payments — averaging $6105.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$542K
- Exelixis Inc.$501K
- Macrogenics, Inc.$116K
- Janssen Research & Development, LLC$80K
- Incyte Corporation$59K
- Merck$47K
- plus $54K from 3 others
What the payments were for
- Food & beverage$194100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $132 |
| Osteocentric Technologies, Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $15 |
How this compares
$194 in reported general payments places this provider in the 25th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 39 | $143,751 |
| CreonLipase/Protease/Amylase | 14 | $76,647 |
| ZarxioFilgrastim-Sndz | 26 | $39,383 |
| EliquisApixaban | 21 | $21,086 |
| XareltoRivaroxaban | 16 | $9,443 |
| Ondansetron OdtOndansetron | 57 | $782 |
| Potassium Chloride | 43 | $639 |
| Prochlorperazine Maleate | 54 | $570 |
| Dexamethasone | 12 | $104 |
| Levothyroxine Sodium | 22 | $91 |
| Olanzapine | 11 | $82 |
| Amoxicillin | 12 | $7 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.